Clinical Trial Detail

NCT ID NCT01519323
Title BRIM-P
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

melanoma

Therapies

Vemurafenib

Age Groups: child

Additional content available in CKB BOOST